Logo image of MRUS

MERUS NV (MRUS) Stock Fundamental Analysis

NASDAQ:MRUS - NL0011606264 - Common Stock

66.1 USD
-1.18 (-1.75%)
Last: 8/28/2025, 4:10:09 PM
66.1 USD
0 (0%)
After Hours: 8/28/2025, 4:10:09 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to MRUS. MRUS was compared to 547 industry peers in the Biotechnology industry. While MRUS has a great health rating, there are worries on its profitability. MRUS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MRUS has reported negative net income.
MRUS had a negative operating cash flow in the past year.
MRUS had negative earnings in each of the past 5 years.
In the past 5 years MRUS always reported negative operating cash flow.
MRUS Yearly Net Income VS EBIT VS OCF VS FCFMRUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

MRUS has a Return On Assets (-39.33%) which is comparable to the rest of the industry.
MRUS's Return On Equity of -45.80% is fine compared to the rest of the industry. MRUS outperforms 67.64% of its industry peers.
Industry RankSector Rank
ROA -39.33%
ROE -45.8%
ROIC N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.9%
ROIC(3y)N/A
ROIC(5y)N/A
MRUS Yearly ROA, ROE, ROICMRUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRUS Yearly Profit, Operating, Gross MarginsMRUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

MRUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRUS has more shares outstanding
The number of shares outstanding for MRUS has been increased compared to 5 years ago.
There is no outstanding debt for MRUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MRUS Yearly Shares OutstandingMRUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MRUS Yearly Total Debt VS Total AssetsMRUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 20.02 indicates that MRUS is not in any danger for bankruptcy at the moment.
MRUS's Altman-Z score of 20.02 is amongst the best of the industry. MRUS outperforms 92.32% of its industry peers.
MRUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.02
ROIC/WACCN/A
WACC7.4%
MRUS Yearly LT Debt VS Equity VS FCFMRUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

MRUS has a Current Ratio of 8.39. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.39, MRUS is in the better half of the industry, outperforming 75.32% of the companies in the same industry.
MRUS has a Quick Ratio of 8.39. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
MRUS has a Quick ratio of 8.39. This is in the better half of the industry: MRUS outperforms 75.50% of its industry peers.
Industry RankSector Rank
Current Ratio 8.39
Quick Ratio 8.39
MRUS Yearly Current Assets VS Current LiabilitesMRUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

MRUS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -93.03%.
Looking at the last year, MRUS shows a very strong growth in Revenue. The Revenue has grown by 59.78%.
The Revenue has been growing slightly by 3.03% on average over the past years.
EPS 1Y (TTM)-93.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-175.31%
Revenue 1Y (TTM)59.78%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%20.4%

3.2 Future

MRUS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.69% yearly.
MRUS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 91.19% yearly.
EPS Next Y-83.55%
EPS Next 2Y-23.71%
EPS Next 3Y-7.01%
EPS Next 5Y27.69%
Revenue Next Year44.59%
Revenue Next 2Y20.38%
Revenue Next 3Y64.34%
Revenue Next 5Y91.19%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MRUS Yearly Revenue VS EstimatesMRUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
MRUS Yearly EPS VS EstimatesMRUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRUS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRUS Price Earnings VS Forward Price EarningsMRUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRUS Per share dataMRUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

MRUS's earnings are expected to decrease with -7.01% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.71%
EPS Next 3Y-7.01%

More info and screens

0

5. Dividend

5.1 Amount

MRUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERUS NV

NASDAQ:MRUS (8/28/2025, 4:10:09 PM)

After market: 66.1 0 (0%)

66.1

-1.18 (-1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)10-29 2025-10-29/amc
Inst Owners97.7%
Inst Owner Change-4.43%
Ins Owners0.38%
Ins Owner Change0.71%
Market Cap5.00B
Analysts87.5
Price Target93.46 (41.39%)
Short Float %6.41%
Short Ratio6.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-55.78%
Min EPS beat(2)-83.38%
Max EPS beat(2)-28.18%
EPS beat(4)1
Avg EPS beat(4)-30.51%
Min EPS beat(4)-83.38%
Max EPS beat(4)51.7%
EPS beat(8)3
Avg EPS beat(8)-11.64%
EPS beat(12)6
Avg EPS beat(12)-12.33%
EPS beat(16)10
Avg EPS beat(16)3.02%
Revenue beat(2)1
Avg Revenue beat(2)97.51%
Min Revenue beat(2)-37.2%
Max Revenue beat(2)232.22%
Revenue beat(4)2
Avg Revenue beat(4)58.34%
Min Revenue beat(4)-37.2%
Max Revenue beat(4)232.22%
Revenue beat(8)3
Avg Revenue beat(8)23.48%
Revenue beat(12)5
Avg Revenue beat(12)13.5%
Revenue beat(16)9
Avg Revenue beat(16)14.23%
PT rev (1m)0.21%
PT rev (3m)7.32%
EPS NQ rev (1m)-5.59%
EPS NQ rev (3m)-23.47%
EPS NY rev (1m)-23.05%
EPS NY rev (3m)-37.29%
Revenue NQ rev (1m)-5.01%
Revenue NQ rev (3m)18.21%
Revenue NY rev (1m)-6.35%
Revenue NY rev (3m)13.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 88.91
P/FCF N/A
P/OCF N/A
P/B 5.94
P/tB 5.95
EV/EBITDA N/A
EPS(TTM)-5.54
EYN/A
EPS(NY)-5.07
Fwd EYN/A
FCF(TTM)-4.14
FCFYN/A
OCF(TTM)-4.14
OCFYN/A
SpS0.74
BVpS11.13
TBVpS11.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.33%
ROE -45.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.54%
Cap/Sales 0.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.39
Quick Ratio 8.39
Altman-Z 20.02
F-Score3
WACC7.4%
ROIC/WACCN/A
Cap/Depr(3y)275.9%
Cap/Depr(5y)195.01%
Cap/Sales(3y)10.83%
Cap/Sales(5y)7.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-175.31%
EPS Next Y-83.55%
EPS Next 2Y-23.71%
EPS Next 3Y-7.01%
EPS Next 5Y27.69%
Revenue 1Y (TTM)59.78%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%20.4%
Revenue Next Year44.59%
Revenue Next 2Y20.38%
Revenue Next 3Y64.34%
Revenue Next 5Y91.19%
EBIT growth 1Y-76.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.41%
EBIT Next 3Y17.46%
EBIT Next 5YN/A
FCF growth 1Y-97.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-108.38%
OCF growth 3YN/A
OCF growth 5YN/A